human ewing sarcoma ews cell lines  (ATCC)

Journal: Oncotarget

Article Title: Oncolytic reovirus inhibits angiogenesis through induction of CXCL10/IP-10 and abrogation of HIF activity in soft tissue sarcomas

doi: 10.18632/oncotarget.21423

Figure Lengend Snippet: (A) The effects of oncolytic reovirus on sarcoma cells. Sarcoma cell lines were treated for 72 h with the indicated concentrations of Reolysin. Cell viability (based on quantification of mitochondrial metabolism) was determined by MTT assay. Mean ± SD, n = 3. (B) HT-1080 sarcoma cells are sensitive to Reolysin-mediated cell death. Cells were treated for 48 h with Reolysin and DNA fragmentation was measured by PI-FACS analysis. Mean ± SD, n = 3. *Indicates a significant difference compared to Controls, p < 0.05. (C) Reovirus replicates in HT-1080 cells. Cells were treated with 30 PFU/cell Reolysin for 48 h and stained with an anti-reovirus antibody. Immunocytochemistry reveals significant reovirus replication in infected HT-1080 cells. Reovirus replication was not observed in A673, SK-LMS-1, and RH30 cell lines. (D) Quantification of reovirus replication in sarcoma cell lines. Cells were treated with 30 PFU/cell Reolysin for 48 h and reovirus replication was visualized by electron microscopy. Arrows denote reovirus particles. The percentages of reovirus infected cells were manually counted in 3 distinct areas of 100 cells (top). The fraction of cytoplasm containing viral particles was quantified using ImageJ software. (bottom) Mean ± SD, n = 3.

Article Snippet: HT-1080 (fibrosarcoma), SK-LMS-1 (leiomyosarcoma), and A673 (Ewing’s sarcoma) cell lines were obtained from the American Type Culture Collection (ATCC) (Rockville, MD).

Techniques: MTT Assay, Staining, Immunocytochemistry, Infection, Electron Microscopy, Software

Journal: Oncotarget

Article Title: Oncolytic reovirus inhibits angiogenesis through induction of CXCL10/IP-10 and abrogation of HIF activity in soft tissue sarcomas

doi: 10.18632/oncotarget.21423

Figure Lengend Snippet: (A) SK-LMS-1, HT-1080, A673, and RH30 sarcoma cells (1 x 10 7 /mouse) were injected into the flanks of nude mice. When tumors reached approximately 150 mm 3 in size, mice were randomized into groups and treated with 5 x 10 8 TCID 50 Reolysin Q7D, 5 mg/kg temsirolimus QD or both agents. Tumors were measured twice weekly. Mean ± SEM, n = 10. *Indicates a significant difference compared to vehicle or **either single agent treatment, p < 0.05. (B) Reolysin and temsirolimus are well tolerated in vivo . Animal body weight was determined at the end of the study to quantify drug-induced weight loss. Mean ± SD, n = 10. (C) Reolysin and temsirolimus increase CXCL10 expression. CXCL10 expression was measured by IHC and staining intensity was quantified using ImageJ software. Mean ± SD, n = 5. *Indicates a significant difference compared to single agent treatments, p < 0.05.

Article Snippet: HT-1080 (fibrosarcoma), SK-LMS-1 (leiomyosarcoma), and A673 (Ewing’s sarcoma) cell lines were obtained from the American Type Culture Collection (ATCC) (Rockville, MD).

Techniques: Injection, In Vivo, Expressing, Staining, Software